News | February 24, 2023
Sanofi India posts Q4 CY22 PAT at Rs. 130.9 Cr
The company has reported total income of Rs. 691.9 crores during the quarter ended December 31, 2022
The company has reported total income of Rs. 691.9 crores during the quarter ended December 31, 2022
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Clinical studies are expected to start in Q2 2023.
Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Becomes the 1st diagnostics company in India to launch BD MAX MDR TB test
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
Subscribe To Our Newsletter & Stay Updated
